Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WOONSOCKET, R.I. , Nov. 9, 2022 /PRNewswire/ -- CVS Health® (NYSE: CVS) is actively preparing for Hurricane Nicole's landfall in Florida.

CVS Health supporting customers, patients, members and colleagues as Hurricane Nicole approaches

SA Contributor Daniel Jones talks CVS's surprisingly fantastic recent earnings with WSB podcast host Julie Morgan. Cano Health deal - don't worry too much about the rumors.

CVS: Surprisingly Fantastic Q3 Earnings

WOONSOCKET, R.I. , Nov. 4, 2022 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced that Executive Vice President and Chief Financial Officer Shawn Guertin will participate in a fireside chat with investors at the 31st Annual Credit Suisse Healthcare Conference on November 9, 2022, at approximately 8:35 am pacific time.

CVS Health to Present at the 31st Annual Credit Suisse Healthcare Conference

There's good news and bad news for the healthcare giant.

Is CVS Health Stock a Buy After the Q3 Earnings Beat?

Walgreens

Walmart

CVS Health Corp (NYSE:CVS), Walgreens Boots Alliance Inc (NASDAQ:WBA), and Walmart Inc (NYSE:WMT) have agreed to pay about $13.8 billion to resolve thousands of US state and local lawsuits accusing the pharmacy chains of mishandling opioid pain drugs. CVS said on Wednesday it had agreed to pay about $5 billion over 10 years, and Walgreens said that it had agreed to pay about $5.7 billion over 15 years.

Walmart, Walgreens and CVS, agree to pay $13.8B to settle US opioid claims

The stock responded well to third-quarter earnings, but the company also lost a frightening $3.4 billion in the third quarter.

Should You Buy CVS Health Stock Now?

Robust sales growth across all three operating segments drive CVS Health's (CVS) top line.

CVS Health (CVS) Q3 Earnings Surpass Estimates, View Up

CVS Health Corporation (NYSE:CVS ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Larry McGrath - Senior Vice President Business Development and Investor Relations Karen Lynch - President and Chief Executive Officer Shawn Guertin - Executive Vice President and Chief Financial Officer Daniel Finke - President, Healthcare Benefits Alan Lotvin - President, Pharmacy Services Michelle Peluso - Executive Vice President. Chief Customer Officer and Co-President, Retail Prem Shah - Executive Vice President, Chief Pharmacy Officer and Co-President, Retail Conference Call Participants Lisa Gill - JPMorgan Justin Lake - Wolfe Research Michael Cherny - Bank of America A.J.

CVS Health Corporation (CVS) Q3 2022 Earnings Call Transcript

Shares of pharmacy retailer CVS Health (NYSE: CVS ) stock are trending and up 3% today after the Woonsocket, Rhode Island-based company reported better-than-expected third-quarter earnings and announced that it has reached a $5.2 billion settlement related to the opioid crisis. While the Q3 print was a definite positive for the company and CVS stock, analysts are also applauding the opioid settlement, noting that the financial penalty will be paid out over several years and that it brings some much-needed closure and clarity to the company and its future finances.

$5 Billion Opioid Settlement Boosts CVS Stock. Here's Why.

CVS announced Wednesday it had agreed to pay $5 billion, while Walgreens and Walmart also reportedly reached billion-dollar settlement deals.

CVS, Walgreens And Walmart Agree To Pay More Than $10 Billion To Settle Opioid Claims

CVS Health (CVS) delivered earnings and revenue surprises of 5.03% and 6.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CVS Health (CVS) Beats Q3 Earnings and Revenue Estimates

CVS raises its guidance for full-year earnings. But the headline news is a $5 billion settlement over the opioid crisis.

CVS Stock Soars After Big Beat-and-Raise. It Also Will Pay $5 Billion in Opioid Settlement.

CVS Health reported a quarterly loss of more than $3 billion to cover its share of a global opioid settlement in the works with various states, counties and local governments.

CVS Reports $3 Billion Loss To Cover Its Share Of Global Opioid Settlement

CVS Health Corp. stock CVS, -0.08% soared 5% in premarket trade Wednesday, after the company announced a $5 billion settlement of opioid claims and third-quarter earnings blew past estimates. The company swung to a loss of $3.409 billion, or $2.60 a share, for the third quarter, after income of $1.587 billion, or $1.20 a share, in the year-earlier period.

CVS Health stock jumps 5% premarket after earnings beat, opioid settlement

CVS Health Corp on Wednesday raised its annual profit forecast after topping quarterly estimates on strong performance at its health insurance and pharmacy benefit management businesses, sending its shares up 1% in premarket trade.

CVS Health lifts forecast as PBM, insurance units drive profit beat

CVS Health Corp. CVS, -0.08% said Wednesday it has reached an agreement in principle to pay about $5 billion over the next 10 years to settle opioid lawsuits and claims made by states, political subdivisions and counties and cities and tribes in the U.S. The payments will start in 2023. The company said it is not admitting liability or wrongdoing, but that the settlement will fully cover claims dating back a decade or more.

CVS Health to pay about $5 billion over 10 years to settle opioid claims brought by states, cities and others in the U.S.

CVS Health beat Wall Street's expectations in its third quarter earnings report.

CVS Health raises outlook as third quarter results beat estimates

WOONSOCKET, R.I. , Nov. 2, 2022 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended September 30, 2022.

CVS HEALTH REPORTS THIRD QUARTER RESULTS

WOONSOCKET, R.I. , Nov. 2, 2022 /PRNewswire/ -- CVS Health® (NYSE: CVS) announced today that it has agreed in principle to a financial resolution designed to substantially resolve all opioid lawsuits and claims against the company by states, political subdivisions, such as counties and cities, and tribes in the United States.

CVS Health reaches agreement in principle for global opioid settlement

The drugstore chain agreed to make the payments over 10 years to states, cities and tribes that sued over opioid abuse.

CVS to Pay $5 Billion to Settle Opioid Lawsuits

Abbott Labs

Medical Properties Trust

Adding these stocks to your portfolio could lead to a lifetime of passive income.

3 Dividend-Paying Stocks to Buy in November and Hold Forever

CVS, Walgreens and Walmart – the nation's three largest retail U.S. pharmacies — have agreed “in principle” to pay $12 billion in a massive global settlement to resolve claims they contributed to the opioid epidemic.

Reports: CVS, Walgreens And Walmart Agree To $12 Billion Opioid Settlement

CVS Health Corp , Walgreens Boots Alliance Inc and Walmart Inc have tentatively agreed to pay more than $12 billion to resolve thousands of state and local government lawsuits accusing the chains of mishandling opioid painkillers, Bloomberg News reported on Tuesday.

CVS, Walmart, Walgreens reach tentative $12 bln Opioid pact - Bloomberg News

CVS Health (NYSE: CVS) is scheduled to report its Q3 2022 results on Wednesday, November 2. We expect CVS stock to trade lower post the results announcement, with Q3 revenue and earnings likely falling below the consensus estimates, primarily weighed down by higher costs and lower contribution.

Will CVS Health Stock Rise Post Q3 Results?

Walgreens and CVS Health aren't done gobbling up primary care assets even after spending billions of dollars in the last two years.

News for CVS Health Stock (CVS)